Overview

Emicizumab in Patients With Acquired Hemophilia A

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Genentech, Inc.